基本信息
views: 665
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
During my tenure in academia, I lead numerous clinical trials that advanced the field and resulted in the U.S. Food and Drug Administration approval of two novel agents for patients with Hodgkin's lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades, and the approval of the first immune checkpoint inhibitor for lymphoma. During the same time, our groups’ efforts at MDACC and MSKCC resulted in 11 new approved indications for the treatment of patients with different types of lymphoid malignancies.
I have published more than 300 papers in peer-reviewed journals, served as the principal investigator of more than 60 clinical trials, including national and international multi-centre studies, and led two independent National Cancer Institute–funded Specialized Programs of Research Excellence at MDACC and MSKCC that focused on novel drug development for patients with lymphoma. I also led a Leukemia & Lymphoma Society-sponsored Specialized Center of Research program focusing on developing a second-generation CAR (chimeric antigen receptor) T-cell therapy for patients with blood cancers. I am a past member of the Scientific Advisory Board of the Lymphoma Research Foundation.
I have published more than 300 papers in peer-reviewed journals, served as the principal investigator of more than 60 clinical trials, including national and international multi-centre studies, and led two independent National Cancer Institute–funded Specialized Programs of Research Excellence at MDACC and MSKCC that focused on novel drug development for patients with lymphoma. I also led a Leukemia & Lymphoma Society-sponsored Specialized Center of Research program focusing on developing a second-generation CAR (chimeric antigen receptor) T-cell therapy for patients with blood cancers. I am a past member of the Scientific Advisory Board of the Lymphoma Research Foundation.
Research Interests
Papers共 753 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Paola Ghione,Salma Ahsanuddin,Efrat Luttwak, Sabela Bobillo Varela,Reiko Nakajima,Laure Michaud,Kanika Gupta, Anastasia Navitski,David Straus,M. Lia Palomba,Alison Moskowitz,Ariela Noy,
HAEMATOLOGICAno. 1 (2024): 200-208
Paola Ghione,Salma Ahsanuddin,Efrat Luttwak, Sabela Bobillo Varela,Reiko Nakajima,Laure Michaud,Kanika Gupta, Anastasia Navitski,David Straus,M Lia Palomba,Alison Moskowitz,Ariela Noy,
Caitlin M. Stewart,Laure Michaud,Karissa Whiting,Reiko Nakajima, Chelsea Nichols, Stephanie De Frank,Paul A. Hamlin,Matthew J. Matasar,John F. Gerecitano,Pamela Drullinsky,Audrey Hamilton,David Straus,
crossref(2023)
Lale Kostakoglu,Maurizio Martelli,Laurie H. Sehn, Andrew Davies,Marek Trneny,Michael Herold, Umberto Vitolo, Wolfgang Hiddemann,Judith Trotman,Andrea Knapp,Federico Mattiello,Tina G. Nielsen,
EJHAEMno. 4 (2023): 1042-1051
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus,M. Lia Palomba, Alison Moskowitz, Ariela Noy,
Haematologicano. 1 (2023)
crossref(2023)
crossref(2023)
HemaSphereno. S3 (2023): e5749555-e5749555
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn